|Bid||142.00 x 1100|
|Ask||146.00 x 1000|
|Day's Range||141.79 - 171.01|
|52 Week Range||53.40 - 194.75|
|Beta (5Y Monthly)||1.05|
|PE Ratio (TTM)||809.24|
|Earnings Date||Apr 28, 2021 - May 03, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||150.13|
NVCR earnings call for the period ending December 31, 2020.
Novocure's streak of bullish revenue growth is expected to diminish, an analyst said Thursday as NVCR stock tumbled on several delayed clinical studies. Earnings also came in light.
The company announced delays of several clinical studies, with one analyst also predicting slower growth ahead.